Grafa
PACS Group revenue hits $1.42B as California incentive payments drive 184% profit spike
PACS Group revenue hits $1.42B as California incentive payments drive 184% profit spike

PACS Group revenue hits $1.42B as California incentive payments drive 184% profit spike

Share

PACS Group (NYSE:PACS) delivered a dominant first quarter for 2026, reporting an 11.2% revenue increase and a nearly threefold jump in net income.

The Salt Lake City-based post-acute giant benefited from a combination of organic occupancy gains and a significant windfall from California’s state incentive programs, prompting management to raise its full-year profitability outlook.

For the quarter ended March 31, 2026, revenue rose to $1.42 billion.

Net income skyrocketed 184.2% to $80.7 million, or $0.51 per share, compared to $28.4 million in the prior-year period.

This bottom-line surge was amplified by $16.3 million in payments from California’s Workforce & Quality Incentive Program (WQIP), which rewards facilities for hitting specific care and staffing benchmarks.

The company’s operational metrics outperformed industry averages across the board.

Overall occupancy reached 90.8%, significantly higher than the roughly 79% national average for skilled nursing facilities.

In its "mature" facility cohort, occupancy was even tighter at 94.8%.

Following the strong results, PACS raised its full-year 2026 adjusted EBITDA guidance to a range of $605 million to $625 million, up from the previous $555 million to $575 million.

Notably, the new guidance excludes potential contributions from future acquisitions, signaling that the company is confident in its ability to grow through its existing 324-facility portfolio.

To further signal confidence to the market, the Board of Directors approved a new $250 million share repurchase authorization.

The company also highlighted its real estate strategy, having deployed $86.5 million into strategic facility investments during the quarter.

With $795.1 million in available liquidity and a net leverage ratio of just 0.1x, PACS remains one of the most well-capitalized players in the fragmented U.S. post-acute market.

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.